FLT3L treatment in vivo promoted the differentiation of CD103+ DC progenitors in the bone marrow and their expansion at the tumor site by enforcing IRF8 signaling, resulting in accumulation of immature CD103+ DCs and accumulation of Treg cells at the tumor site. This evidence concerns the gene IRF8 and neoplasm.